EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
- FDA
Related events
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- EMA adopted a positive opinion and the European Commission granted marketing authorization for the drug Hopledo.
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.
- Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
- Cresco Labs faced a class action lawsuit in Illinois after marketing products without the required FDA approval.